<DOC>
	<DOC>NCT00171873</DOC>
	<brief_summary>Placebo-controlled prospective randomized phase III study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut</brief_summary>
	<brief_title>Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Therapynaive patients with histologically confirmed diagnosis of a locally inoperable or metastasized welldifferentiated neuroendocrine tumor of the midgut curative surgery impossible twodimensional tumor formation assessable by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Age â‰¥ 18 Karnofskyindex &gt; 60 written informed consent proliferation index for Ki67 hypersensitivity to octreotide poorly differentiated or small cell neuroendocrine tumors primary tumor outside of the midgut prior treatment with somatostatinanalogue &gt; 4 weeks prior treatment with alphainterferon, chemotherapy, or chemoembolisation participation in any other clinical trial pregnancy or lactation no secondary malignancy in anamnesis; with the exception of patients without any manifestation of the secondary malignancy (without relapse) after curative therapy within the last five years severe decompensated organ malfunction (heart, liver insufficiency) Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Double blind</keyword>
	<keyword>Phase III</keyword>
	<keyword>Disease</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Midgut</keyword>
</DOC>